Autism is a pervasive developmental disorder diagnosed in early childhood. Abnormalities of serotonergic neurotransmission have been reported in autism. Serotonin transporter (5-HTT), which modulates serotonin levels, is a major therapeutic target in autism. Therefore, factors that regulate 5-HTT expression might be implicated in autism. One candidate 5-HTT-regulatory protein is the presynaptic protein, syntaxin 1A (STX1A). We examined the association of STX1A with autism in a trio association study using DNA samples from 249 AGRE trios with autistic probands. Only male probands were selected, since autism is more prevalent among males. The probands of 102 trios had IQ>70, and were considered as high functioning autism (HFA). In transmission disequilibrium test (TDT) analysis, rs2293485 (p=0.034) and rs4717806 (p=0.033) showed nominal associations with HFA ; modest haplotype association was also observed. The SNPs that showed associations were related to early developmental abnormalities (ADI-R_D). We further compared STX1A mRNA expression in the lymphocytes of drug-naive HFA patients (n=12) and age-and sex-matched controls (n=13). STX1A expression in the HFA group was significantly higher (p=0.001) than that of controls. Thus, we suggest a possible role of STX1A in the pathogenesis of HFA. During early childhood, there is a period of high brain serotonin synthesis that is disrupted in autistic children ; STX1A might influence the serotonergic system during this stage of neurodevelopment, as implied by the association with ADI-R_D.
Introduction
Autism is a pervasive developmental disorder diagnosed in early childhood, characterized by social and communication deficits in combination with restricted and repetitive behaviours and interests (Kanner, 1943) . Based on converging evidence from diverse studies, the serotonin (5-HT) system can be considered as a logical candidate in autism pathology. The 5-HT system has been found to be developmentally dysregulated in autism (Anderson, 1994) . 5-HT acts as a trophic and differentiation factor (Lavdas et al., 1997) , in addition to its role as a neurotransmitter. Hyperserotonaemia has been observed in the platelets of subjects with autism (Ciaranello, 1982 ; Hanley et al., 1977) .
Several studies have reported the association of serotonin transporter (5-HTT) polymorphisms with autism (Betancur et al., 2002 ; Cook et al., 1997 ; Klauck et al., 1997 ; Tordjman et al., 2001 ; Yirmiya et al., 2001) . 5-HTT effects the recycling of 5-HT by mediating its presynaptic reuptake on termination of serotonergic neurotransmission ; it is also the major target of selective serotonin reuptake inhibitors (SSRIs) (Moore et al., 2004) , which have been proven to be efficient in reducing compulsive and stereotyped behaviours and hyperactivity in autism patients (McDougle et al., 1996) . 5-HTT (SLC6A4) is located in 17q11.2, which has been implicated as an autism linkage region ; however, other studies have reported different results with stronger linkage findings (Freitag, 2007) . 5-HTT gene promoter variants have been suggested to exert a detectable, albeit small effect on 5-HT blood levels in autistic individuals (Lesch et al., 1996) ; however, as suggested by Persico et al. (2002) enhanced 5-HT blood levels in autism patients, but not in first-degree relatives with the promoter variant, indicate interactive contributions to hyperserotonaemia both by 5-HTT variants and by other autism-related loci. Thus, factors that regulate the cell surface expression of 5-HTT might also have a crucial role in the regulation of serotonergic neurotransmission, and therefore, in the pathology of autism.
One candidate 5-HTT-regulatory protein is the presynaptic protein, syntaxin 1A (STX1A) ; this 35-kDa membrane protein belonging to the syntaxin family (Bennett et al., 1992 Inoue et al., 1992) was originally identified as a neuron-specific antigen (Barnstable et al., 1985) . Together with the synaptosome-associated protein 25 kDa (SNAP-25) and the vesicle-associated membrane protein (VAMP), STX1A forms the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex, which is vital for chemical neurotransmission (Rothman, 1994 ; Sollner et al., 1993) .
In-vitro studies have shown that STX1A interacts with 5-HTT, regulating the subcellular localization and expression of 5-HTT (Haase et al., 2001 ; Quick, 2002) . STX1A gene is located at 7q11.23 ; recently, speech delay and autism spectrum behaviours have been found to be associated with duplication of 7q11.23 (Berg et al., 2007 ; Depienne et al., 2007) .
In this trio association study, we examined the SNP and haplotype associations of STX1A with autism ; we also examined the association of STX1A SNPs with ADI-R phenotypic data. Further, we compared the expression of STX1A mRNA in the peripheral blood lymphocytes (PBL) of drug-naive autistic patients and control subjects, since lymphocytes are considered as a convenient and accessible alternative to brain samples for biochemical and genetic investigations of the functions of central nervous system (CNS) (Gladkevich et al., 2004) . We also examined the relationship between mRNA expression and genotypes in the lymphocyte samples.
Method

Association study
Subjects
This study was approved by the Ethics Committee of Hamamatsu University School of Medicine. We obtained DNA samples from trio families recruited to the Autism Genetic Resource Exchange [AGRE (http:// www.agre.org) ; Geschwind et al., 2001] ; 249 trio families with a male proband diagnosed for autism according to Autism Diagnostic Interview -Revised (ADI-R ; Lord et al., 1994) and Autism Diagnostic Observation Schedule (ADOS ; Lord et al., 1989) , were selected. Out of the 249 trios, 235 trios were derived from multiplex families ; only male probands [age 9.65¡4.87 yr (mean¡S.D.)] were selected, since autism has a strong gender bias with a 4 : 1 (male : female) gender ratio. Additional selection criteria required that (i) there be no possible non-idiopathic autism flag and (ii) all the trios be Caucasian. ADI-R data was available for all the 249 affected individuals ; however, ADOS testing was available for only 163, and intelligence quotient (IQ) testing for only 112 out of the 249 autistic individuals. The autistic probands of 102 trios had IQ>70, and were considered as the high functioning autism (HFA) group.
We had taken care to exclude the commonly known genetic causes of autism (e.g. fragile X syndrome), and other neurological disorders such as tuberous sclerosis and neurofibromatosis.
Mutation screening and marker selection
The genomic structure of STX1A is based on the UCSC May 2004 draft assembly of human genome (http:// www.genome.ucsc.edu). STX1A consists of 10 exons spanning a genomic stretch of 20.42 kb (mRNA 2064 bases) (Figure 1 ). In 20 unrelated autism samples selected randomly from among the AGRE probands, all the exons, splice boundaries, and 5k-and 3k-flanking regions of the gene were screened for polymorphisms by direct sequencing of the respective PCR products. Primer sets used for PCR amplification are listed in Table 1 . PCR was performed with an initial denaturation at 95 xC for 12 min, followed by 35 cycles at 94 xC for 30 s, 55-60 xC (optimized for each primer pair) for 30 s, 72 xC for 1 min, and a final extension at 72 xC for 7 min, using AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA, USA). Direct sequencing of PCR products was done using the BigDye Terminator Cycle Sequencing kit v3.1 (Applied Biosystems) in ABI PRISM 3100 Genetic Analyzer (Applied Biosystems).
Additional SNPs were selected using the information from International HapMap Project (http:// www.hapmap.org) and National Centre for Biotechnology Information (NCBI dbSNP : http://www.ncbi. nlm.nih.gov/SNP). On the basis of their genomic locations and minor allele frequencies (MAF >0.1) in the Caucasian population, 10 SNPs were chosen for our analysis, to span the STX1A gene as evenly as possible. The SNPs used in the study, and their locations are shown in Table 2 .
Genotyping
Assay-on-demand/Assay-by-design SNP genotyping products (Applied Biosystems) were used to score SNPs, based on the TaqMan assay method (Ranade et al., 2001 ). Genotypes were determined using the ABI 7900 Sequence Detection System (SDS ; Applied Biosystems), and analysed using SDS version 2.0 software (Applied Biosystems).
Statistical analysis
PedCheck program version 1.1 (http://www.watson. hgen.pitt.edu) was used to identify and eliminate all Mendelian inheritance inconsistencies in the trio genotype data. All the SNPs were tested for Hardy-Weinberg Equilibrium (HWE) using the Haploview software version 3.2 (http://www.broad. mit.edu/mpg/haploview). Markers were tested for association by transmission disequilibrium test (TDT), using the TDTPHASE program of the UNPHASED software package version 2.403 (http://portal.litbio. org) ; expectation maximization (EM) algorithm was used to resolve uncertain haplotypes, to infer missing genotypes and to provide maximum-likelihood estimation of frequencies.
One-way analysis of variance [ANOVA ; GraphPad Prism, version 4.00 (GraphPad Software, San Diego, CA, USA)] was used to examine the variability in the distribution of ADI-R phenotypic data [ADI-R_A (social interaction), ADI-R_BV (verbal communication), ADI-R_C (restricted, repetitive and stereotyped patterns of behaviour), ADI-R_D (developmental abnormality prior to 36 months)] across the homozygous and heterozygous genotypes of SNPs that showed associations in single SNP TDT.
Linkage disequilibrium (LD) plot was constructed using the r 2 correlation coefficient (Devlin and Risch, 1995) pair-wise LD values between markers were estimated using Haploview software. Subsequently, associations of haplotypes (frequency >0.01) belonging to the various haploblocks of STX1A were also examined using Haploview.
Gene expression analysis
Subjects
We obtained blood samples from 12 drug-naive autistic patients (age 21.4¡2.31 yr) and 13 agematched (22.3¡1.93 yr) healthy controls. All the patients and controls were males, and of Japanese origin ; written informed consent was obtained from all the participants. The autistic patients were diagnosed according to ADI-R (Lord et al., 1994) , by trained and certified psychiatrists (K.J.T., A.S.). All patients met the autism criteria of DSM-IV (APA, 1994) and ICD-10 (WHO, 1992) . The patients underwent screening, and were excluded if they had any major medical or psychiatric conditions. We had taken care to exclude the commonly known genetic causes of autism (e.g. fragile X syndrome), and other neurological disorders such as tuberous sclerosis and neurofibromatosis. All the patients were of the HFA type ; the average IQ scores were measured by the Wechsler Adult Intelligence Scale -Revised (WAIS-R ; Wechsler, 1981, Japanese version) .
We used the following instruments for the assessment of autistic symptoms. Comorbid anxiety and depressive symptoms were assessed using the Hamilton Anxiety Rating Scale (HAMA ; Hamilton, 1959 , Japanese version) and the Hamilton Depression Rating Scale (HAMD ; Hamilton, 1960 , Japanese version), respectively. Obsessional/repetitive behaviours were clinically rated using the Yale-Brown Obsessive-Compulsive Scale (YBOCS ; Goodman et al., 1989a, b, Japanese version) . Additional aggression symptoms were also assessed using the aggression questionnaire (AQ ; Buss and Perry, 1992 , translation in Japanese). A faux pas detection task was used to measure theory of mind (Baron-Cohen et al., 1999 , Stone et al., 2003 . All the evaluations were conducted by a trained research psychiatrist (K.N.).
All the controls were free of medications, and underwent screening to exclude neurological, developmental, or psychiatric disorders and mental retardation ; none of them met any of the relevant criteria of DSM-IV. The average IQ of the control subjects (measured by WAIS-R, Wechsler, 1981 , Japanese version) did not differ significantly from that of the HFA patients. 
5k-GCAGTGATCAGCGACTGAGA-3k Exon 10 UTR3 E10U-3F 5k-CACATGGTGCTGCTTTTCAG-3k 300 E10U-3R 5k-GACTGACTGCAGCCTGCTT-3k UTR, Untranslated region.
Lymphocyte RNA
Peripheral blood (20 ml) was drawn from the cubital vein into EDTA-containing plastic syringes. Lymphocytes were isolated from blood samples by the Ficoll-Paque gradient method, and total RNA was extracted using RNAzolB reagent (Sawady, Tokyo, Japan) according to the manufacturer's instructions. RNA samples were quantified by analysing the absorbance at 260 nm in a UV spectrophotometer.
Complementary DNA (cDNA) was synthesized by first-strand reverse transcriptase (RT) reaction using Random Primer and M-MLV reverse transcriptase (Invitrogen, CA, USA). We had maintained similar conditions during the collection and processing of all the samples since circadian regulation of STX1A has been reported (Allaman-Pillet et al., 2004) . The blood samples were collected at around 10:00 hours on the days assigned for sample collection. Lymphocyte isolation and RNA extraction were done immediately thereafter, under standard conditions.
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR)
Real-time qRT-PCR analysis was performed using ABI PRISM 7900 Sequence Detection System (Applied Biosystems). TaqMan primer/probes for STX1A and for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) that served as the endogenous reference, were purchased from Applied Biosystems (Assay-onDemand TM gene expression products Hs00195648 and Hs99999905, respectively). All reactions were performed in duplicate, according to the manufacturer's protocol. A comparative threshold cycle (C T ) method validation experiment was performed to check if the efficiencies of target and reference amplifications were approximately equal (the slope of the log input amount vs. DC T <0.1). One sample was randomly chosen as the calibrator and was amplified in each plate to correct for the experimental differences among consecutive PCR runs. The amounts of STX1A mRNA were normalized to the endogenous reference and expressed relative to the calibrator as 2 xDDCT (comparative C T method).
Statistical analysis
Statistical calculations were performed using SPSS statistical package, version 11.0.1 (SPSS Co. Ltd, Tokyo, Japan) and GraphPad Prism. The difference in STX1A expression between groups was analysed using t test. Correlation between the various clinical features of HFA group and STX1A expression was examined by Spearman's rank correlation test. Further, regression analysis was carried out to check the effect of comorbidities, including obsessioncompulsion (YBOCS scores) and aggression, on STX1A expression. 
Relationship between mRNA expression and genotypes
All the samples from the mRNA expression study were genotyped for the SNPs that showed associations in the trio association study. Using the Kruskal-Wallis test, we examined the relationship between genotypes and mRNA expression.
Results
Association study
Mutation screening
No new mutations were observed in the coding or regulatory regions of the gene, other than the SNPs already reported.
Single SNP TDT
Mendelian inheritance inconsistencies were not observed for any of the SNPs. More than 98 % of the genotypes were scored for each SNP ; none of the SNPs showed deviation from HWE.
TDT was performed separately for the whole set of 249 trios and for the HFA subgroup of 102 trios ; the results are shown in Table 2 . In the TDT of HFA trios, SNP04 (p=0.034, OR 1.54, 95 % CI 1.03-2.29) and SNP08 (p=0.033, OR 0.63, 95 % CI 0.41-0.96) showed nominal associations. Overtransmission was observed for the minor allele T (56.07 %) of SNP04 (rs941298 ; exon 3, D68D) and for the minor allele A (57.69 %) of SNP08 (rs4717806). SNP03 (p=0.054), SNP05 (p= 0.053), SNP09 (p=0.050) and SNP10 (p=0.050) showed tendencies for association with HFA. The global p value, however, was not significant (p=0.124).
None of the SNPs showed significant association in the TDT of 249 trios.
Association with ADI-R phenotypic data
We examined the associations of ADI-R phenotypic data (ADI-R_A, ADI-R_BV, ADI-R_C, and ADI-R_D) with the SNPs that showed nominal associations in single SNP TDT. In the HFA trios, significant association with ADI-R_D scores was observed for SNP08 (p=0.036) ; ADI-R_D was lower in the A/A group of this SNP (Figure 2a) . We also examined the associations of SNPs that showed tendency for association in single SNP TDT. SNP03 (p=0.040), SNP09 (p=0.036) and SNP10 (p=0.029) showed significant associations with ADI-R_D ; the scores were lower in the A/A group of SNP03, in the C/C group of SNP09 and in the C/C group of SNP10 (Figure 2b -d, respectively). After adjusting for IQ effects with univariate analysis of variance, there were only tendencies for association with ADI-R_D (SNP08, p=0.070 ; SNP03, p=0.070 ; SNP09, p=0.070 ; SNP10, p=0.055).
No associations were observed with other phenotypic data. In the whole group of 249 trios, there were no significant associations with any of the ADI-R scores.
LD analysis
LD analysis identified a single haploblock across the STX1A gene, comprising SNP03 to SNP10 (Figure 3) . The LD pattern observed in our study is similar to that reported for the 30 CEU (CEPH) trios in the HapMap project.
Haplotype TDT
The results of haplotype association analysis are shown in Table 3 . The haplotype ATACCTCC showed a nominal association in the HFA subgroup of 102 trios (p=0.044) ; however, this was not significant after the permutation test (10 000 permutations). None of the haplotypes showed any significant association in the 249 trios.
Lymphocyte gene expression analysis
Descriptive clinical data of the autism samples is provided in Table 4 . STX1A expression in the drug-naive HFA group (0.38¡0.39) was found to be significantly higher (t=x4.37, d.f.=14, p=0.001) than that of the control group (0.17¡0.06) (Figure 4) . No significant correlation was observed between any of the clinical features of HFA group and STX1A expression (Table 4) . Further, regression analysis showed that there is no effect of YBOCS/aggression on STX1A expression.
Relationship between mRNA expression and genotypes
By Kruskal-Wallis test, the relationship between genotypes and STX1A mRNA expression was examined for SNP04 and SNP08, which showed nominal associations with HFA in TDT analysis. SNP08 showed a tendency for gene dose effect, with the following trend : expression of A/A genotype (mean¡S.D.) (0.243¡0.162)<expression of A/T genotype (0.293¡ 0.143)<expression of T/T genotype (0.462¡0.023) ; however, the difference was not statistically significant.
Discussion
In this study, STX1A mRNA expression was significantly higher in the lymphocytes of drug-naive HFA patients compared with controls. Lymphocytes are considered as excellent neural probes for studying neuropsychiatric disorders due to (i) altered lymphocyte functions in neuropsychiatric conditions, (ii) expression of neuroactive proteins and processes in lymphocytes, and (iii) similarities of hormonal effects on the nervous system processes and lymphocyte physiology (reviewed by Gladkevich et al., 2004) . In the present study, there was no significant correlation between STX1A expression and any of the clinical features of the HFA group ; therefore, altered STX1A expression may be implicated in the general pathophysiology of HFA, rather than in the symptoms of the disease. The possibilities of using the enhanced expression of STX1A as a peripheral marker in the diagnosis of HFA may be explored. However, our study is limited by small sample size ; therefore, replication in a larger sample size is warranted.
Lymphoblastoid cells lines have been reported as viable tools for identifying the genes associated with autism (Baron et al., 2006 ; Hu et al., 2006 ; Nishimura et al., 2007) . There is a close association between the state of the immune system, particularly lymphocytes, and major psychiatric disorders including autism (Ashwood et al., 2006 ; Krause et al., 2002) . STX1A is a neuron-specific antigen (Barnstable et al., 1985) , which, in association with SNAP-25 and VAMP, forms the SNARE complex that is vital for chemical neurotransmission (Rothman, 1994 ; Sollner et al., 1993) . In a Elevated expression of STX1A in autism 1079
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http://ijnp.oxfordjournals.org/ process similar to the exocytosis of neurotransmitters, STX1A and other SNARE proteins are involved in a process of exocytosis of lytic granules, mediating target cell death in the PBLs that play a pivotal role in the body's defence against infection (Hong, 2005) . The presence of sympathetic fibres in lymphoid tissues suggests a direct contact area for neural signalling cascade with the immune cells (Felten et al., 1987) . Thus, lymphocyte STX1A expression might be indicative of CNS expression. In animal models, STX1A expression has been shown to be more or less constant after the embryonic and immediate postnatal stages (Biranowska et al., 2002 ; Shimohama et al., 1998) . Therefore, the expression pattern of STX1A in our study subjects with an average age of 22 yr might be comparable to the STX1A expression during their first years of life, which is the most critical period for the formation of neural wiring patterns. In the trio association study, nominal SNP and haplotype associations were observed with HFA. None of the SNP and haplotype associations will remain significant after multiple testing correction ; however, it is difficult to apply a Bonferroni correction in this study, since strong LD was observed between SNP03 and SNP10. Further, single genes are likely to have only small individual effects in complex disorders like autism. Among the two SNPs that showed nominal associations with HFA, rs2293485 is a synonymous exonic SNP, while rs4717806 is an intronic SNP. The other SNPs that showed tendencies for association are also intronic SNPs. Therefore, the associated SNPs may not have a direct influence on STX1A expression. It is possible that the expression is regulated by additional trans-acting factors in a network of genes involving STX1A. Considering sample homogeneity, we had selected predominantly high-functioning trio samples, where all the subjects were strictly diagnosed with autistic disorder. Since mental retardation consists of various aetiologies, HFA samples can be considered to be relatively free from non-specific environmental or genetic risks for their impairments. We had used all available AGRE cases that satisfied our strict selection criteria at the time of subject selection.
We observed an association of ADI-R_D scores with the SNPs that showed nominal associations or tendencies for association with HFA. This observation in HFA patients who had been diagnosed for autism is interesting, since ADI-R_D reflects developmental abnormalities observed in autism prior to 36 months ; delayed speech, unusual socio-emotional reactions and poor attentions to and exploration of the environment, are among the first clinically noticeable behavioural symptoms of autism during the second and third years of life (Dahlgren and Gillberg, 1989 ; De Giacomo and Fombonne, 1998) . Since autism is a pervasive developmental disorder, neuroanatomical, neurochemical and neurobiological abnormalities should precede the appearance of clinical symptoms. The importance of 5-HT in several aspects of prenatal and postnatal brain development that are related to autism is well documented. Humans undergo a period of high brain 5-HT synthesis capacity during early childhood, which is disrupted in autistic children (Chugani et al., 1999) . Thus, STX1A might be involved in the pathogenesis of autism by influencing the serotonergic system, during the early stages of brain development. However, after adjustment for IQ, there were only tendencies for association with ADI-R_D.
There was no relation with other ADI-R subscores (ADI-R_A, ADI-R_BV, ADI-R_C), which reflect the severity of autism.
During the postnatal stages of neurodevelopment, the expression of 5-HTT might be a prerequisite for the neurodevelopmental functions exerted by 5-HT. Invitro studies have shown that 5-HTT expression is regulated by STX1A (Haase et al., 2001 ; Quick, 2002) . In cultured cells, STX1A has been found to interact with 5-HTT, modulating the cell-surface expression of 5-HTT (Haase et al., 2001 ). Cells transfected with STX1A cDNA showed a decrease in the number of 5-HTT molecules expressed on the cell surface ; the decrease in 5-HTT expression was suggested to be caused either by an inhibition of the recycling of previously internalized 5-HTT or by a blocking of the trafficking of newly synthesized 5-HTT to the plasma membrane. Studies using thalamocortical neuronal cultures also have shown that STX1A affects the localization and cell-surface expression of 5-HTT (Quick, 2002) . Thus, STX1A might be suggested to influence the serotonergic system by modulating the expression of 5-HTT.
An alternate mode of action of STX1A may be through its interaction with the glutamatergic system (Fan et al., 2006 ; Yu et al., 2006) . Glutamate, the major excitatory neurotransmitter in the brain, plays a vital role in brain development, affecting neuronal migration, neuronal differentiation, axon genesis, and neuronal survival (Coyle et al., 2002) . STX1A promotes the endocytic sorting of the glutamate transporter EAAC1, leading to inhibition of glutamate transport (Yu et al., 2006) . Several studies have implicated abnormalities of glutamatergic neurotransmission in the pathophysiology of autism (reviewed by McDougle et al., 2005) . Glutamate-related genes have also been shown to be important in the pathology of autism (Szatmari et al., 2007) .
In conclusion, we suggest a possible role of STX1A in the pathogenesis of HFA ; this is the first report of an association between STX1A and HFA. In autism, mental retardation implies the involvement of more risk factors and genes ; this might be the reason that the autism group, as a whole, was not associated with STX1A. The association of STX1A with the HFA group may thus, indicate a protective role against mental retardation. However, considering our sample size, it may be too premature to draw such a conclusion ; the elevated expression of STX1A might also be secondary to other metabolic changes in HFA. Therefore, further studies into the functional impact of STX1A in HFA are warranted.
